U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia-Reference-Cited by-同舟云学术

U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia

Published:2017-06-19 Issue:12 Volume:64 Page:e26657
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Ehrlich Lori A.¹^ORCID,Kwitkowski Virginia E.¹,Reaman Gregory¹,Ko Chia-Wen²,Nie Lei²,Pazdur Richard¹,Farrell Ann T.¹

Affiliation:

1. Office of Hematology and Oncology Products; Center for Drug Evaluation and Research; U.S. Food and Drug Administration; Silver Spring Maryland

2. Office of Biostatistics; Center for Drug Evaluation and Research; U.S. Food and Drug Administration; Silver Spring Maryland

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference8 articles.

1. Immune thrombocytopenic purpura of childhood;Nugent;Hematology Am Soc Hematol Educ Program,2006

2. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports;Terrell;Am J Hematol,2010

3. Management of immune thrombocytopenic purpura: an update;Warrier;Ochsner J,2012

4. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group;Rodeghiero;Blood,2009

5. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review;Neunert;J Thromb Haemost,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review;Journal of Clinical Medicine;2023-06-06

2. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia;BMC Cancer;2023-05-31

3. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia;2022-10-12

4. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system;Journal of Clinical Pharmacy and Therapeutics;2022-05-29

5. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol;BMJ Open;2021-08